Cancer natural history, complications and prognosis
|
Cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cancer natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Cancer natural history, complications and prognosis |
|
Cancer natural history, complications and prognosis in the news |
|
Blogs on Cancer natural history, complications and prognosis |
|
Risk calculators and risk factors for Cancer natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Prognosis
Cancer has a reputation for being a deadly disease. While this certainly applies to certain particular types, the truths behind the historical connotations of cancer are increasingly being overturned by advances in medical care. Some types of cancer have a prognosis that is substantially better than nonmalignant diseases such as heart failure and stroke.
Progressive and disseminated malignant disease has a substantial impact on a cancer patient's quality of life, and many cancer treatments (such as chemotherapy) may have severe side-effects. In the advanced stages of cancer, many patients need extensive care, affecting family members and friends. Palliative care solutions may include permanent or "respite" hospice nursing.
Cancer patients, for the first time in the history of oncology, are visibly returning to the athletic arena and workplace. Patients are living longer with either quiescent persistent disease or even complete, durable remissions. The stories of Lance Armstrong, who won the Tour de France after treatment for metastatic testicular cancer, or Tony Snow, who was working as the White House Press Secretary as of June, 2007 despite relapsed colon cancer, continue to be an inspiration to cancer patients everywhere.
Cancer-associated thrombosis (CAT)
Randomized controlled trials have examined the role of anticoagulation for the primary prevention of thrombosis among patients with cancer[1][2].
The prediction of patients at high-risk of thrombosis in cancer has been reviewed[3].
References
- ↑ Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T; et al. (2019). "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer". N Engl J Med. 380 (8): 720–728. doi:10.1056/NEJMoa1814630. PMID 30786186. Review in: Ann Intern Med. 2019 Jun 18;170(12):JC67
- ↑ Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A; et al. (2019). "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer". N Engl J Med. 380 (8): 711–719. doi:10.1056/NEJMoa1814468. PMID 30511879. Review in: Ann Intern Med. 2019 Mar 19;170(6):JC29
- ↑ Gervaso L, Dave H, Khorana AA (2021). "Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review". JACC CardioOncol. 3 (2): 173–190. doi:10.1016/j.jaccao.2021.03.001. PMC 8352228 Check
|pmc=value (help). PMID 34396323 Check|pmid=value (help).